{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:13:23Z","timestamp":1788513203153,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) in patients aged \u2265\u200980\u2009years represents a growing and clinically distinct population that remains underrepresented in clinical trials. Consequently, treatment decisions are often extrapolated from younger or \u201cfit\u201d cohorts, limiting their applicability in routine practice. While targeted therapies (i.e., novel agents such as Bruton tyrosine kinase inhibitors [BTKi] and BCL2 inhibitors) have substantially improved outcomes compared with chemoimmunotherapy, their use in very elderly patients is associated with higher rates of treatment discontinuation, dose reductions, and adverse events. Conventional frailty tools, largely based on comorbidity burden and renal function, fail to capture key age\u2010related vulnerabilities, such as functional decline, cognitive impairment, and reduced physiological reserve. Emerging data suggest that chronological age \u2265\u200980\u2009years may identify a subgroup with specific clinical behavior and toxicity profiles that are insufficiently characterized by existing assessment models. In summary, elderly patients (aged \u2265\u200980\u2009years) with CLL should be considered a distinct population requiring individualized, safety\u2010oriented therapeutic approaches. Dedicated clinical trials and adapted treatment algorithms are needed to optimize outcomes in this setting.<\/jats:p>","DOI":"10.1111\/ejh.70248","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:16:21Z","timestamp":1782177381000},"page":"864-879","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged \u2265\u200980\u2009Years"],"prefix":"10.1111","volume":"117","author":[{"given":"Driss","family":"Chaoui","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Victor Dupouy  Argenteuil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, AP\u2010HP, H\u00f4pital Saint\u2010Antoine Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132018","author":"Howlader N.","year":"2021"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15604"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001596\u2010z"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30262\u20102"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00293\u20105"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27747"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100602\u2010x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028550"},{"key":"e_1_2_7_12_1","volume-title":"Age and Sex Composition: 2020","author":"Blakeslee L.","year":"2023"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165\u20101781(92)90005\u2010N"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31554"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005716"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103993"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028899"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8347"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01789\u2010X"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70322"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029905"},{"key":"e_1_2_7_22_1","unstructured":"French Innovative Leukemia Organization (FILO) SFH Guidelines for Chronic Lymphocytic Leukemia(2025)."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014474"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025027378"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_7_29_1","unstructured":"R.Guieze E.Ferrant F.Merabet et\u00a0al. Acalabrutinib Time\u2010Limited Strategy in Elderly Unfit CLL Patients. ASH Annual Meeting Abstracts(2025)."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201002265"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201002380"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00452\u20107"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3249"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24715"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025525"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/20.6.649"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008758"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(18)30601\u20107"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12485"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:22:36Z","timestamp":1788510156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/ejh.70248"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70248","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"2026-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}